All News

Yvonne Saenger, director of melanoma and immunotherapy at Columbia University Medical Center, discusses the side effects patients should look out for when they are on immunotherapy, and how to determine if they are experiencing normal therapy-induced fatigue or if they are suffering from a hormone reaction and should go see their medical team.

Eileen O'Reilly discusses the current barriers in treating pancreatic cancer, as well as what she sees for the future of the disease.

The addition of custirsen did not improve survival for a subset of patients with prostate cancer in a phase 3 trial.

Fortunately, cancer awareness has increased, and so have treatment options. One of my goals is to encourage patients and families to maximize their use of available resources to minimize post-treatment challenges and discomfort.

Making our own decisions is empowering after facing the trauma of breast cancer.

The best use of liquid biopsies in late-stage non–small cell lung cancer (NSCLC) will be to augment tissue biopsies at initial diagnosis and to evaluate patients for second- and third-line therapies.

With more treatment options than ever, Maura N. Dickler discusses some of the deciding factors for patients with ER positive metastatic breast cancer.

Two-time cancer survivor shares her thoughts about that small, quiet voice.

Charlie Gourley discusses where Lynparza fits in with ovarian cancer care.

Alexander I. Sankin comments on some of the ongoing developments in bladder cancer.

By funding research and connecting patients with researchers, doctors and clinical trials, End Brain Cancer is hoping that more people will survive the disease.

A cancer diagnosis can send people reeling. Who should you listen to as you decide the next step? Who should you ignore?

Whoever said there's no way to make time stand still clearly never had to endure the excruciating wait for scan results.

Recent years brought many advances in the field of immunotherapy in melanoma, but more still needs to be done.

Keytruda is showing benefit to some patients with sarcoma, according to interim results from a phase 2 trial.

Surprisingly, Opdivo did not improve progression-free survival for a subset of patients with lung cancer in the CheckMate-026 trial. CURE sat down with Paul A. Bunn Jr to discuss why.

Of the possible 1,000,000 Lynch syndrome carriers in the USA alone, it is estimated that only about 5 percent have been tested.

Why know the odds if they're useless?

New standards were just established for patients undergoing surgery for DCIS.

Jorge Garcia offers insight about the benefits of Cabometyx and the drug's impact on RCC.

A recent study found that certain genetic mutations could play a role in cisplatin-induced hearing loss.